CDK4 and aneurysmal bone cyst: Interestingly, in the REVERT study, a significant interaction between the treatment arm and previous CDK4/6i treatment was observed for ORR and PFS, suggesting that ET could improve the antitumor efficacy of eribulin in luminal ABC patients refractory to CDK4/6i.